Association Between Plasma Caffeine and Other Methylxanthines and Metabolic Parameters in a Psychiatric Population Treated With Psychotropic Drugs Inducing Metabolic Disturbances
Fiche du document
9 novembre 2018
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.3389/fpsyt.2018.00573
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/30473668
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1664-0640
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_EFD90D5BB70B4
info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer
Mots-clés
Psychiatry and Mental healthSujets proches
Methyltheobromine Trimethyldioxopurine Guaranine Dihydrotrimethylpurinedione Trimethylxanthine Coffeine Trimethyldihydropurinedione TheineCiter ce document
Aurélie Delacrétaz et al., « Association Between Plasma Caffeine and Other Methylxanthines and Metabolic Parameters in a Psychiatric Population Treated With Psychotropic Drugs Inducing Metabolic Disturbances », Serveur académique Lausannois, ID : 10.3389/fpsyt.2018.00573
Métriques
Partage / Export
Résumé
Importance: Multiple studies conducted in the general population identified an association between self-reported coffee consumption and plasma lipid levels. To date, no study assessed whether and which plasma methylxanthines (caffeine and/or its metabolites, i.e., paraxanthine, theophylline, and theobromine) are associated with plasma lipids. In psychiatric patients, an important coffee consumption is often reported and many psychotropic drugs can induce a rapid and substantial increase of plasma lipid levels. Objective: To determine whether plasma methylxanthines are associated with metabolic parameters in psychiatric patients receiving treatments known to induce metabolic disturbances. Design, Setting, and Participants: Data were obtained from a prospective study including 630 patients with metabolic parameters [i.e., body mass index (BMI), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), and fasting triglycerides (TG)] monitored routinely during psychotropic treatment. Exposures: Plasma methylxanthines levels. Main Outcomes and Measures: Metabolic variables including BMI and plasma lipid levels. Results: Multivariate analyses indicated that BMI, TC, HDL-C, and non-HDL-C increased significantly with increasing total methylxanthines (pcorrected